| Dr Rebecca Martin, MD, PHD | |
|
975 E 3rd St, Chattanooga, TN 37403-2147 | |
| (423) 778-7628 | |
| Not Available |
| Full Name | Dr Rebecca Martin |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 975 E 3rd St, Chattanooga, Tennessee |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548656861 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD0000055415 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cedar Recovery Center Of Middle Tennessee, Llc | 0446671440 | 29 |
News Archive
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
A successful and effective malaria vaccine could be available in Africa by 2015 revealed a co-inventor of the shot against the killer disease, Tuesday. Advance trials of the RTS,S vaccine against falciparum malaria are under way in seven African countries. This variety of malaria is the deadliest and trials are said to be showing encouraging results according to GlaxoSmithKline researcher Joe Cohen, who has been working on developing the vaccine for over 20 years.
Researchers at UCLA's Jonsson Cancer Center have uncovered the mechanism by which an antibody blocks the growth of prostate cancer in animal models, a discovery that could pave the way for development of a new molecularly targeted therapy.
Last week's failure of the budget super committee, despite its super powers, is only the latest breakdown in an attempt at compromise in Washington. Politicians keep trying to fashion failsafe solutions to the capital's uncompromising mind-set, without understanding that there is no external escape from an environment that rewards those who stand tenaciously on their principles and demonize their opponents. Members of Congress need to change their minds about compromise, or voters will need to change the members of Congress.
Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.
› Verified 3 days ago
| Entity Name | Tennessee River Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396282463 PECOS PAC ID: 8022387349 Enrollment ID: O20170629002555 |
News Archive
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
A successful and effective malaria vaccine could be available in Africa by 2015 revealed a co-inventor of the shot against the killer disease, Tuesday. Advance trials of the RTS,S vaccine against falciparum malaria are under way in seven African countries. This variety of malaria is the deadliest and trials are said to be showing encouraging results according to GlaxoSmithKline researcher Joe Cohen, who has been working on developing the vaccine for over 20 years.
Researchers at UCLA's Jonsson Cancer Center have uncovered the mechanism by which an antibody blocks the growth of prostate cancer in animal models, a discovery that could pave the way for development of a new molecularly targeted therapy.
Last week's failure of the budget super committee, despite its super powers, is only the latest breakdown in an attempt at compromise in Washington. Politicians keep trying to fashion failsafe solutions to the capital's uncompromising mind-set, without understanding that there is no external escape from an environment that rewards those who stand tenaciously on their principles and demonize their opponents. Members of Congress need to change their minds about compromise, or voters will need to change the members of Congress.
Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.
› Verified 3 days ago
| Entity Name | Cedar Recovery Center Of Middle Tennessee, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801345285 PECOS PAC ID: 0446671440 Enrollment ID: O20200529001321 |
News Archive
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
A successful and effective malaria vaccine could be available in Africa by 2015 revealed a co-inventor of the shot against the killer disease, Tuesday. Advance trials of the RTS,S vaccine against falciparum malaria are under way in seven African countries. This variety of malaria is the deadliest and trials are said to be showing encouraging results according to GlaxoSmithKline researcher Joe Cohen, who has been working on developing the vaccine for over 20 years.
Researchers at UCLA's Jonsson Cancer Center have uncovered the mechanism by which an antibody blocks the growth of prostate cancer in animal models, a discovery that could pave the way for development of a new molecularly targeted therapy.
Last week's failure of the budget super committee, despite its super powers, is only the latest breakdown in an attempt at compromise in Washington. Politicians keep trying to fashion failsafe solutions to the capital's uncompromising mind-set, without understanding that there is no external escape from an environment that rewards those who stand tenaciously on their principles and demonize their opponents. Members of Congress need to change their minds about compromise, or voters will need to change the members of Congress.
Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rebecca Martin, MD, PHD 975 E 3rd St, Chattanooga, TN 37403-2147 Ph: (423) 778-7628 | Dr Rebecca Martin, MD, PHD 975 E 3rd St, Chattanooga, TN 37403-2147 Ph: (423) 778-7628 |
News Archive
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
A successful and effective malaria vaccine could be available in Africa by 2015 revealed a co-inventor of the shot against the killer disease, Tuesday. Advance trials of the RTS,S vaccine against falciparum malaria are under way in seven African countries. This variety of malaria is the deadliest and trials are said to be showing encouraging results according to GlaxoSmithKline researcher Joe Cohen, who has been working on developing the vaccine for over 20 years.
Researchers at UCLA's Jonsson Cancer Center have uncovered the mechanism by which an antibody blocks the growth of prostate cancer in animal models, a discovery that could pave the way for development of a new molecularly targeted therapy.
Last week's failure of the budget super committee, despite its super powers, is only the latest breakdown in an attempt at compromise in Washington. Politicians keep trying to fashion failsafe solutions to the capital's uncompromising mind-set, without understanding that there is no external escape from an environment that rewards those who stand tenaciously on their principles and demonize their opponents. Members of Congress need to change their minds about compromise, or voters will need to change the members of Congress.
Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.
› Verified 3 days ago
Joseph Kerby Gray, MD Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 2525 De Sales Ave, Chattanooga, TN 37404 Phone: 423-495-2525 | |
Ronald A. Gracy Ii, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 941 Spring Creek Rd, Chattanooga, TN 37412 Phone: 423-894-7870 Fax: 865-539-8008 | |
Dr. Jocelyn May De Guzman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1755 Gunbarrel Rd, Chattanooga, TN 37421 Phone: 423-680-8534 | |
Dr. Jeffrey Durant Clinkscales, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-7628 | |
Dr. Shelley L Murphy, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1018 Blackford Street, Chattanooga, TN 37403 Phone: 423-778-7000 | |
Samuel Wilson, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2525 Desales Ave, Chattanooga, TN 37404 Phone: 423-697-0014 Fax: 423-648-6280 | |
Dr. James B Bardoner, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-7296 Fax: 423-778-8086 |